Cyclo Therapeutics, Inc. – NASDAQ:CYTH

Cyclo Therapeutics stock price today

$0.721
+0.12
+20.5%
Financial Health
0
1
2
3
4
5
6
7
8
9

Cyclo Therapeutics stock price monthly change

-52.54%
month

Cyclo Therapeutics stock price quarterly change

-52.54%
quarter

Cyclo Therapeutics stock price yearly change

-63.54%
year

Cyclo Therapeutics key metrics

Market Cap
16.86M
Enterprise value
N/A
P/E
-0.37
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
2.29
Price/Book
6.00
PEG ratio
0.04
EPS
-1
Revenue
1.12M
EBITDA
-20.12M
Income
-19.39M
Revenue Q/Q
32.83%
Revenue Y/Y
-15.51%
Profit margin
-144531884.55%
Oper. margin
-153024910.64%
Gross margin
-63458428.81%
EBIT margin
-153024910.64%
EBITDA margin
-1786.87%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cyclo Therapeutics stock price history

Cyclo Therapeutics stock forecast

Cyclo Therapeutics financial statements

Cyclo Therapeutics, Inc. (NASDAQ:CYTH): Profit margin
Jun 2023 117.11K -4.63M -3958.79%
Sep 2023 495.47K -4.77M -962.98%
Dec 2023 311.39K -5.64M -1811.95%
Mar 2024 202.45K -4.34M -2145.25%
Cyclo Therapeutics, Inc. (NASDAQ:CYTH): Analyst Estimates
Mar 2024 202.45K -4.34M -2145.25%
Sep 2025 600K -4.97M -828.98%
Oct 2025 524K -4.43M -845.56%
Dec 2025 424K -5.00M -1179.81%
  • Analysts Price target

  • Financials & Ratios estimates

Cyclo Therapeutics, Inc. (NASDAQ:CYTH): Earnings per share (EPS)
2022-11-11 -0.53 -0.5
2023-03-17 -1.3924 -0.59
Cyclo Therapeutics, Inc. (NASDAQ:CYTH): Debt to assets
Jun 2023 4642667 6.12M 131.98%
Sep 2023 5597066 6.64M 118.81%
Dec 2023 13247538 8.49M 64.09%
Mar 2024 7163890 6.55M 91.48%
Cyclo Therapeutics, Inc. (NASDAQ:CYTH): Cash Flow
Jun 2023 -3.47M 0 3.40M
Sep 2023 -4.04M 0 5.00M
Dec 2023 -4.29M -2.42K 11.74M
Mar 2024 -6.18M 0 -69.28K

Cyclo Therapeutics alternative data

Cyclo Therapeutics, Inc. (NASDAQ:CYTH): Employee count
Aug 2023 9
Sep 2023 9
Oct 2023 9
Nov 2023 9
Dec 2023 9
Jan 2024 9
Feb 2024 9
Mar 2024 8
Apr 2024 8
May 2024 8
Jun 2024 8
Jul 2024 8

Cyclo Therapeutics other data

0.30% -19.90%
of CYTH is owned by hedge funds
19.20K -1.26M
shares is hold by hedge funds

Cyclo Therapeutics, Inc. (NASDAQ:CYTH): Insider trades (number of shares)
Period Buy Sel
Apr 2023 898210 0
Aug 2023 8000000 0
Oct 2023 3260482 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
RAFAEL HOLDINGS, INC. 10 percent owner
Warrant to Purchase Common Stock 2,766,467 $0.95 $2,628,144
Purchase
OSTRONIC FRANCIS PATRICK director
Warrant to Purchase Common Stock 65,869 $0.95 $62,576
Purchase
SIEGER MARKUS director
Warrant to Purchase Common Stock 65,869 $0.95 $62,576
Purchase
FINE N SCOTT director, officer.. Warrant to Purchase Common Stock 329,342 $0.95 $312,875
Purchase
TATE JEFFREY director, officer.. Warrant to Purchase Common Stock 32,935 $0.95 $31,288
Purchase
RAFAEL HOLDINGS, INC. 10 percent owner
Common Stock Warrants (Right to Buy) 4,000,000 $1.25 $5,000,000
Purchase
RAFAEL HOLDINGS, INC. 10 percent owner
Common Stock, par value $0.0001 per share 4,000,000 $1.25 $5,000,000
Purchase
TATE JEFFREY director, officer.. Common Stock 29,941 $0.71 $21,258
Purchase
TATE JEFFREY director, officer.. Warrant to Purchase Common Stock 29,941 $0.71 $21,258
Purchase
FINE N SCOTT director, officer.. Common Stock 299,402 $0.71 $212,575
Friday, 20 December 2024
prnewswire.com
Thursday, 21 November 2024
globenewswire.com
Thursday, 14 November 2024
zacks.com
Friday, 23 August 2024
prnewswire.com
Thursday, 22 August 2024
prnewswire.com
accesswire.com
Thursday, 15 August 2024
businesswire.com
Wednesday, 14 August 2024
zacks.com
Monday, 29 July 2024
businesswire.com
Tuesday, 25 June 2024
businesswire.com
Thursday, 30 May 2024
businesswire.com
Thursday, 16 May 2024
businesswire.com
Monday, 18 March 2024
businesswire.com
Thursday, 14 March 2024
businesswire.com
Monday, 29 January 2024
businesswire.com
Thursday, 5 October 2023
Business Wire
Tuesday, 10 January 2023
Business Wire
Wednesday, 7 September 2022
Business Wire
Monday, 8 August 2022
Business Wire
Thursday, 21 July 2022
Business Wire
Monday, 11 July 2022
Business Wire
Tuesday, 21 June 2022
Business Wire
Thursday, 10 March 2022
Business Wire
Tuesday, 8 February 2022
Business Wire
Thursday, 20 January 2022
Business Wire
Saturday, 1 January 2022
Seeking Alpha
Wednesday, 17 November 2021
Pulse2
Tuesday, 16 November 2021
Seeking Alpha
Wednesday, 10 November 2021
Business Wire
Tuesday, 19 October 2021
Business Wire
  • What's the price of Cyclo Therapeutics stock today?

    One share of Cyclo Therapeutics stock can currently be purchased for approximately $0.72.

  • When is Cyclo Therapeutics's next earnings date?

    Unfortunately, Cyclo Therapeutics's (CYTH) next earnings date is currently unknown.

  • Does Cyclo Therapeutics pay dividends?

    No, Cyclo Therapeutics does not pay dividends.

  • How much money does Cyclo Therapeutics make?

    Cyclo Therapeutics has a market capitalization of 16.86M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 21.76% to 1.08M US dollars. Cyclo Therapeutics made a loss 20.06M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.

  • What is Cyclo Therapeutics's stock symbol?

    Cyclo Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CYTH".

  • What is Cyclo Therapeutics's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Cyclo Therapeutics?

    Shares of Cyclo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Cyclo Therapeutics's key executives?

    Cyclo Therapeutics's management team includes the following people:

    • Mr. N. Scott Fine Chief Executive Officer & Director(age: 68, pay: $489,200)
    • Dr. Sharon H. Hrynkow Ph.D. Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Senior Vice President of Medical Affairs(age: 65, pay: $297,860)
    • Dr. Jeffrey L. Tate Chief Operating Officer, Chief Quality Officer & Director(age: 67, pay: $255,140)
  • How many employees does Cyclo Therapeutics have?

    As Jul 2024, Cyclo Therapeutics employs 8 workers.

  • When Cyclo Therapeutics went public?

    Cyclo Therapeutics, Inc. is publicly traded company for more then 25 years since IPO on 3 May 2000.

  • What is Cyclo Therapeutics's official website?

    The official website for Cyclo Therapeutics is cyclotherapeutics.com.

  • Where are Cyclo Therapeutics's headquarters?

    Cyclo Therapeutics is headquartered at 6714 NW 16th Street, Gainesville, FL.

  • How can i contact Cyclo Therapeutics?

    Cyclo Therapeutics's mailing address is 6714 NW 16th Street, Gainesville, FL and company can be reached via phone at +386 4188060.

Cyclo Therapeutics company profile:

Cyclo Therapeutics, Inc.

cyclotherapeutics.com
Exchange:

NASDAQ

Full time employees:

8

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

6714 NW 16th Street
Gainesville, FL 32653

CIK: 0000922247
ISIN: US23254X2018
CUSIP: 550241103